Primary Sclerosing Cholangitis Pipeline Drugs Analysis Report (2023 Updates): FDA Approvals, Clinical Trials, Therapies, by DelveInsight | Genfit, CymaBay Therapeutics, Calliditas Therapeutics, Zydus-Cadila, Cour Pharmaceutical, Mirum Pharmaceuticals

(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Primary Sclerosing Cholangitis pipeline constitutes 14+ key companies continuously working towards developing 14+ Primary Sclerosing Cholangitis treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

"Primary Sclerosing Cholangitis Pipeline Insight, 2023" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Primary Sclerosing Cholangitis Market.

The Primary Sclerosing Cholangitis Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

Some of the key takeaways from the Primary Sclerosing Cholangitis Pipeline Report: https://www.delveinsight.com/sample-request/primary-sclerosing-cholangitis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
• Companies across the globe are diligently working toward developing novel Primary Sclerosing Cholangitis treatment therapies with a considerable amount of success over the years.
• Primary Sclerosing Cholangitis companies working in the treatment market are antifibrotic therapeutics Engitix, GRI Bio, Qing Bile Therapeutics, Sirnaomics, Cascade Pharmaceuticals, Chemomab Therapeutics, Mirum Pharmaceuticals, Pliant Therapeutics, Genfit, CymaBay Therapeutics, Intercept Pharmaceuticals, Cour Pharmaceutical, Gannex Pharma, Ohara Pharmaceutical, Selecta Biosciences, and others, are developing therapies for the Primary Sclerosing Cholangitis treatment
• Emerging Primary Sclerosing Cholangitis therapies in the different phases of clinical trials are- Research programme, GRI-0124, QBT-002, STP707, CS0159, CM 101, Volixibat, PLN-74809, Elafibranor, Seladelpar, Bezafibrate/obeticholic acid, CNP-104, ASC42, OP-724, PDC-E2, and others are expected to have a significant impact on the Primary Sclerosing Cholangitis market in the coming years.
• In June 2023, Chemomab Therapeutics Ltd. (Nasdaq: CMMB), (Chemomab), a clinical-stage biotechnology company developing novel therapeutics to treat rare fibro-inflammatory diseases with high unmet medical needs, announced today that it presented two scientific posters defending the clinical justification for the company's primary sclerosing cholangitis (PSC) programme at EASL 2023, the Annual Congress of the European Association for the Study of the Live
• In March 2023, Pliant Therapeutics, Inc. declared that enrollment has started in a Phase IIa trial of bexotegrast at 320 mg dosed once daily for at least 24 weeks and up to 48 weeks in patients with primary sclerosing cholangitis (PSC), following a favourable independent Data Safety Monitoring Board (DSMB) safety review
• In November 2022, Seladelpar findings in patients with primary biliary cholangitis (PBC) were presented at The Liver Meeting of the American Association for the Study of Liver Diseases (AASLD) in Washington, DC (November 4th-8th), according to CymaBay Therapeutics, Inc
• In August 2022, Ascletis Pharma Inc.-owned Gannex Pharma Co., Ltd. reported that the Farnesoid X Receptor agonist ASC42 for the treatment of PBC had completed its first dosage in the US drug-drug interaction (DDI) study. Upcoming phase III trials in the US, China, and the EU will have additional evidence to support them thanks to the DDI research and continuing phase II clinical trial in PBC patients in China
• In July 2022, The U.S. Food and Drug Administration (FDA) has granted PLN-74809, an oral, dual-selective vß6/vß1integrin inhibitor, Fast Track designation for the potential treatment of primary sclerosing cholangitis (PSC). This was disclosed by Pliant Therapeutics (NASDAQ: PLRX)

Primary Sclerosing Cholangitis Overview
Primary sclerosing cholangitis (PSC) is a cholestatic liver illness that is chronic and progressive and has no known cause. PSC is characterised by inflammation, fibrosis, and/or stricturing of the intra- and/or extrahepatic biliary ducts. PSC often develops over time and might result in cholestasis and liver failure as consequences.

Get a Free Sample PDF Report to know more about Primary Sclerosing Cholangitis Pipeline Therapeutic Assessment-
https://www.delveinsight.com/report-store/primary-sclerosing-cholangitis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Emerging Primary Sclerosing Cholangitis Drugs Under Different Phases of Clinical Development Include:
• Research programme: antifibrotic therapeutics Engitix
• GRI-0124: GRI Bio
• QBT-002: Qing Bile Therapeutics
• STP707: Sirnaomics
• CS0159: Cascade Pharmaceuticals
• CM 101: Chemomab Therapeutics
• Volixibat: Mirum Pharmaceuticals
• PLN-74809: Pliant Therapeutics
• GS-9674: Gilead Sciences
• IMU-838: Immunic
• Elafibranor: Genfit
• Seladelpar: CymaBay Therapeutics
• Bezafibrate/obeticholic acid: Intercept Pharmaceuticals
• CNP-104: Cour Pharmaceutical
• ASC42: Gannex Pharma
• OP-724: Ohara Pharmaceutical
• PDC-E2: Selecta Biosciences

Primary Sclerosing Cholangitis Route of Administration
Primary Sclerosing Cholangitis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
• Oral
• Parenteral
• Intravitreal
• Subretinal
• Topical
• Molecule Type

Primary Sclerosing Cholangitis Molecule Type
Primary Sclerosing Cholangitis Products have been categorized under various Molecule types, such as
• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy
• Product Type

Primary Sclerosing Cholangitis Pipeline Therapeutics Assessment
• Primary Sclerosing Cholangitis Assessment by Product Type
• Primary Sclerosing Cholangitis By Stage and Product Type
• Primary Sclerosing Cholangitis Assessment by Route of Administration
• Primary Sclerosing Cholangitis By Stage and Route of Administration
• Primary Sclerosing Cholangitis Assessment by Molecule Type
• Primary Sclerosing Cholangitis by Stage and Molecule Type

DelveInsight's Primary Sclerosing Cholangitis Report covers around 14+ products under different phases of clinical development like
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Further Primary Sclerosing Cholangitis product details are provided in the report. Download the Primary Sclerosing Cholangitis pipeline report to learn more about the emerging Primary Sclerosing Cholangitis therapies at:
https://www.delveinsight.com/sample-request/primary-sclerosing-cholangitis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Some of the key companies in the Primary Sclerosing Cholangitis Therapeutics Market include:
Key companies developing therapies for Primary Sclerosing Cholangitis are - Genfit, CymaBay Therapeutics, Calliditas Therapeutics, Zydus-Cadila, Cour Pharmaceutical, Mirum Pharmaceuticals, HighTide Biopharma, PRISM Pharma Co, Albireo Pharma, Pliant Therapeutics, GentiBio, Gannex Pharma, Selecta Biosciences, Intercept Pharmaceuticals, Umecrine Cognition, Suzhou Zelgen Biopharmaceuticals, Merck Sharp & Dohme LLC, Kowa Pharmaceuticals, and others.

Primary Sclerosing Cholangitis Pipeline Analysis:
The Primary Sclerosing Cholangitis pipeline report provides insights into
• The report provides detailed insights about companies that are developing therapies for the treatment of Primary Sclerosing Cholangitis with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Primary Sclerosing Cholangitis Treatment.
• Primary Sclerosing Cholangitis key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Primary Sclerosing Cholangitis Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Primary Sclerosing Cholangitis market.
The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about Primary Sclerosing Cholangitis drugs and therapies-
https://www.delveinsight.com/sample-request/primary-sclerosing-cholangitis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Primary Sclerosing Cholangitis Pipeline Market Drivers
• Increasing prevalence of diseases associated with PSC such as liver cancer and inflammatory bowel disease, a rising number of research studies on PSC are some of the important factors that are fueling the Primary Sclerosing Cholangitis Market.

Primary Sclerosing Cholangitis Pipeline Market Barriers
• However, withdrawal of molecules from late clinical stages, lack of skilled professionals or trained expertise and other factors are creating obstacles in the Primary Sclerosing Cholangitis Market growth.

Scope of Primary Sclerosing Cholangitis Pipeline Drug Insight
• Coverage: Global
• Key Primary Sclerosing Cholangitis Companies: , and others
• Key Primary Sclerosing Cholangitis Therapies: Research programme, GRI-0124, QBT-002, STP707, CS0159, CM 101, Volixibat, PLN-74809, Elafibranor, Seladelpar, Bezafibrate/obeticholic acid, CNP-104, ASC42, OP-724, PDC-E2, and others
• Primary Sclerosing Cholangitis Therapeutic Assessment: Primary Sclerosing Cholangitis current marketed and Primary Sclerosing Cholangitis emerging therapies
• Primary Sclerosing Cholangitis Market Dynamics: Primary Sclerosing Cholangitis market drivers and Primary Sclerosing Cholangitis market barriers

Request for Sample PDF Report for Primary Sclerosing Cholangitis Pipeline Assessment and clinical trials-
https://www.delveinsight.com/sample-request/primary-sclerosing-cholangitis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Table of Contents
1. Primary Sclerosing Cholangitis Report Introduction
2. Primary Sclerosing Cholangitis Executive Summary
3. Primary Sclerosing Cholangitis Overview
4. Primary Sclerosing Cholangitis- Analytical Perspective In-depth Commercial Assessment
5. Primary Sclerosing Cholangitis Pipeline Therapeutics
6. Primary Sclerosing Cholangitis Late Stage Products (Phase II/III)
7. Primary Sclerosing Cholangitis Mid Stage Products (Phase II)
8. Primary Sclerosing Cholangitis Early Stage Products (Phase I)
9. Primary Sclerosing Cholangitis Preclinical Stage Products
10. Primary Sclerosing Cholangitis Therapeutics Assessment
11. Primary Sclerosing Cholangitis Inactive Products
12. Company-University Collaborations (Licensing/Partnering) Analysis
13. Primary Sclerosing Cholangitis Key Companies
14. Primary Sclerosing Cholangitis Key Products
15. Primary Sclerosing Cholangitis Unmet Needs
16 . Primary Sclerosing Cholangitis Market Drivers and Barriers
17. Primary Sclerosing Cholangitis Future Perspectives and Conclusion
18. Primary Sclerosing Cholangitis Analyst Views
19. Appendix
20. About DelveInsight

Related Reports:

Primary Sclerosing Cholangitis Market https://www.delveinsight.com/report-store/primary-sclerosing-cholangitis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's 'Primary Sclerosing Cholangitis-Market Insights, Epidemiology, and Market Forecast-2032' report delivers an in-depth understanding of the 7MM, historical and forecasted epidemiology as well as the 7MM market trends in the United States, EU5 (Germany, France, Italy, Spain, and United Kingdom),

Primary Sclerosing Cholangitis Epidemiology https://www.delveinsight.com/report-store/primary-sclerosing-cholangitis-epidemiology-forecast?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's 'Primary Sclerosing Cholangitis Epidemiology Forecast to 2032' report delivers an in-depth understanding of the disease, historical and forecasted Cholangiocarcinoma epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Latest Reports:

Monkeypox Market https://www.delveinsight.com/report-store/monkeypox-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's "Monkeypox Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Monkeypox, historical and forecasted epidemiology as well as the Monkeypox market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Pars Planitis Market
https://www.delveinsight.com/report-store/pars-plantis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's "Pars Plantis Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Pars Plantis, historical and forecasted epidemiology as well as the Pars Plantis market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Patient Monitoring Devices Market
https://www.delveinsight.com/report-store/patient-monitoring-devices-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Patient Monitoring Devices Market By Type Of Devices (Neuromonitoring Devices, Cardiac Monitoring Devices, Respiratory Monitoring Devices, Hemodynamic Monitoring Devices, Blood Glucose Monitoring Systems, And Others), By Application (Cardiology, Neurology, Respiratory, And Others), By End-User (Hospitals & Clinics, Ambulatory Surgical Centers, Home Care Settings, And Others), by geography, is anticipated to grow at a significant CAGR till 2028 owing to the growing prevalence of various chronic disorders and integration of advanced technology in the products

Typhoid Market https://www.delveinsight.com/report-store/typhoid-fever-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's "Typhoid Fever Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Typhoid Fever, historical and forecasted epidemiology as well as the Typhoid Fever market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Zika Virus Market https://www.delveinsight.com/report-store/zika-virus-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's "Zika Virus Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Zika Virus, historical and forecasted epidemiology as well as the Zika Virus market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Opioid Use Disorder Market https://www.delveinsight.com/report-store/opioid-use-disorder-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's "Opioid Use Disorder (OUD) - Market Insights, Epidemiology, and Market Forecast - 2032" report delivers an in-depth understanding of the Opioid Use Disorder (OUD), historical and forecasted epidemiology as well as the Opioid Use Disorder (OUD) market trends in the United States, EU4 (Germany, Spain, Italy, and France) and the United Kingdom, and Japan.

Recent Blog's By DelveInsight:
• Insights Into The Cutaneous T-cell Lymphoma Treatment Market
https://www.delveinsight.com/blog/cutaneous-t-cell-lymphoma-treatment-market?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Roche's HEMLIBRA: A Game Changer in Hemophilia A Treatment Landscape
https://www.delveinsight.com/blog/hemlibra-for-hemophilia-a-treatment?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Emerging Role of Digital Health in the Field of Oncology
https://www.delveinsight.com/blog/digital-health-to-improve-cancer-management?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• How Will Emerging Therapies Drift the Amyotrophic Lateral Sclerosis (ALS) Treatment Landscape
https://www.delveinsight.com/blog/evolving-als-treatment-landscape?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• How are Technological Trends and Innovations Reshaping the Dementia Care
https://www.delveinsight.com/blog/technological-innovations-in-dementia-care?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Assessing the Major Growth and Ongoing Developments in the Clinical Diagnostics Market
https://www.delveinsight.com/blog/clinical-diagnostics-market-outlook?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Non-opioid Analgesics Chronic Pain Treatment: Savior of Underserved Patients
https://www.delveinsight.com/blog/non-opioid-analgesics-for-chronic-pain-treatment?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Limited Availability and Lack of Access are Unlikely to Hinder the Billion-Dollar Alpha-1 Antitrypsin Deficiency (AATD) Treatment Market
https://www.delveinsight.com/blog/alpha-1-antitrypsin-deficiency-treatment-market?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Evaluating the Key Trends and Technologies Shaping the Future of Dentistry https://www.delveinsight.com/blog/emerging-trends-in-dental-care-market?utm_source=blog&utm_medium=promotion&utm_campaign=gpr

Contact Us:
Gaurav Bora
gbora@delveinsight.com
+1(919)321-6187
Healthcare Consulting
https://www.delveinsight.com/consulting-services

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

This release was published on openPR.